CryoLife, Inc. (NYSE:CRY) was downgraded by equities research analysts at BidaskClub from a “hold” rating to a “sell” rating in a research note issued on Tuesday, August 1st.
Several other brokerages also recently issued reports on CRY. Zacks Investment Research raised shares of CryoLife from a “hold” rating to a “buy” rating and set a $21.00 price target for the company in a report on Thursday, June 8th. Northland Securities reissued a “buy” rating and set a $23.50 price target on shares of CryoLife in a report on Friday, April 28th. Two equities research analysts have rated the stock with a sell rating and three have issued a buy rating to the company. CryoLife has a consensus rating of “Hold” and an average target price of $22.00.
CryoLife (NYSE:CRY) traded up 2.72% during midday trading on Tuesday, reaching $18.90. 76,423 shares of the company traded hands. The firm’s 50 day moving average price is $19.30 and its 200 day moving average price is $17.96. CryoLife has a 12 month low of $14.02 and a 12 month high of $20.30. The firm has a market capitalization of $632.13 million, a price-to-earnings ratio of 57.27 and a beta of 0.97.
CryoLife (NYSE:CRY) last issued its earnings results on Monday, July 24th. The medical equipment provider reported $0.12 earnings per share for the quarter, beating the consensus estimate of $0.10 by $0.02. CryoLife had a net margin of 6.16% and a return on equity of 7.41%. The business had revenue of $47.80 million for the quarter, compared to analyst estimates of $47.02 million. During the same period in the previous year, the business earned $0.13 EPS. The firm’s revenue was up 1.5% on a year-over-year basis. On average, analysts expect that CryoLife will post $0.43 earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: This piece of content was first reported by Community Financial News and is owned by of Community Financial News. If you are reading this piece of content on another publication, it was stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be viewed at https://www.com-unik.info/2017/08/14/cryolife-inc-cry-rating-lowered-to-sell-at-bidaskclub-updated.html.
In other CryoLife news, VP Amy Horton sold 9,577 shares of the business’s stock in a transaction dated Tuesday, June 27th. The shares were sold at an average price of $20.00, for a total value of $191,540.00. Following the completion of the transaction, the vice president now directly owns 112,282 shares of the company’s stock, valued at $2,245,640. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 6.00% of the company’s stock.
Several large investors have recently bought and sold shares of the company. Louisiana State Employees Retirement System increased its stake in CryoLife by 0.9% in the second quarter. Louisiana State Employees Retirement System now owns 11,100 shares of the medical equipment provider’s stock worth $221,000 after buying an additional 100 shares during the period. Municipal Employees Retirement System of Michigan increased its stake in CryoLife by 3.2% in the first quarter. Municipal Employees Retirement System of Michigan now owns 6,150 shares of the medical equipment provider’s stock worth $102,000 after buying an additional 190 shares during the period. Arizona State Retirement System increased its stake in CryoLife by 1.4% in the first quarter. Arizona State Retirement System now owns 14,054 shares of the medical equipment provider’s stock worth $234,000 after buying an additional 200 shares during the period. Creative Planning increased its stake in CryoLife by 3.0% in the second quarter. Creative Planning now owns 6,806 shares of the medical equipment provider’s stock worth $136,000 after buying an additional 200 shares during the period. Finally, Wells Fargo & Company MN increased its stake in CryoLife by 0.9% in the second quarter. Wells Fargo & Company MN now owns 31,313 shares of the medical equipment provider’s stock worth $624,000 after buying an additional 271 shares during the period. 69.22% of the stock is owned by institutional investors and hedge funds.
CryoLife Company Profile
CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.
What are top analysts saying about CryoLife Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for CryoLife Inc. and related companies.